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Abstract: 
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related mortality in 
the United States. Aggressive treatment regimens have not changed the disease course, and the 
median survival has just recently reached a year. Several mechanisms are proposed to play a role 
in PDAC therapeutic resistance, including hypoxia, which creates a more aggressive phenotype 
with increased metastatic potential and impaired therapeutic efficacy. AP Endonuclease-1/ 
Redox Effector Factor 1 (APE1/Ref-1) is a multi-functional protein possessing a DNA repair 
function in base excision repair and the ability to reduce oxidized transcription factors, enabling 
them to bind to their DNA target sequences. APE1/Ref-1 regulates several transcription factors 
involved in survival mechanisms, tumor growth, and hypoxia signaling. Here, we explore the 
mechanisms underlying PDAC cell responses to hypoxia and modulation of APE1/Ref-1 redox 
signaling activity, which regulates the transcriptional activation of hypoxia inducible factor 1 
alpha (HIF1α). Carbonic anhydrase IX (CA9) is regulated by HIF1α and functions as part of the 
cellular response to hypoxia to regulate intracellular pH, thereby promoting cell survival. We 
hypothesized that modulating APE1/Ref-1 function will block activation of downstream 
transcription factors, STAT3 and HIF1α, interfering with hypoxia-induced gene expression. We 
demonstrate APE1/Ref-1 inhibition in patient-derived and established PDAC cells results in 
decreased HIF1α−mediated induction of CA9. Furthermore, an ex vivo 3D tumor co-culture 
model demonstrates dramatic enhancement of APE1/Ref-1-induced cell killing upon dual-
targeting of APE1/Ref-1 and CA9. Both APE1/Ref-1 and CA9 are under clinical development, 
therefore these studies have the potential to direct novel PDAC therapeutic treatment. 
  
on October 24, 2017. © 2016 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 17, 2016; DOI: 10.1158/1535-7163.MCT-16-0253 
  4
Introduction: 
Pancreatic ductal adenocarcinoma (PDAC) continues to be the 4th leading cause of cancer 
related mortality in the United States in both genders with a five-year survival rate of 5-7% (1). 
Approximately, 80% of patients present with advanced disease due to local invasion or 
metastatic disease (1, 2). Treatment options for this patient population are limited to palliative 
chemotherapy, and even the most aggressive treatment strategies fail to extend life beyond one 
year for most patients (1, 3). The disappointing result in pancreatic cancer may be explained by 
the complexity of this disease. Several mechanisms of resistance have been proposed to play a 
role in resistance to therapy. The presence of cancer-associated fibroblasts (CAFs) as well as 
other cell types within a desmoplastic stroma, hypoperfusion of the tumor, hypoxia, multidrug 
resistance and other mechanisms have been reported (4-6). Lack of clinical efficacy is due, at 
least in part, to the fibrosis that accompanies the disease. In the studies presented here, tumor-
stroma effects were monitored as the importance of the stroma in PDAC is well-established (7, 
8). Targeting one pathway is very unlikely to alter the natural course of this disease. However 
affecting critical survival mechanisms of this cancer is crucial to produce any positive results (9, 
10).  
Hypoxic conditions in pancreatic tumors are associated with poor prognosis. Oxygen 
deprivation leads to stabilization of hypoxia inducible factor 1 alpha (HIF1α), a transcription 
factor that upregulates a variety of factors that contribute to increased drug resistance, 
proliferation, and migration/invasion in tumor cells (11-13). HIF-1 transcriptional activity 
depends on stabilization of its α subunit, which is targeted for degradation under normoxic 
conditions by proline hydroxylation and subsequent von Hippel-Lindau protein (VHL)-mediated 
ubiquitination. Stable HIF1α dimerizes with the constitutively expressed β subunit to activate 
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genes with hypoxia-response elements (HREs) in their promoters (14, 15). No HIF-1-specific 
inhibitors currently exist, so targeting its vital transcriptional targets and the enzymes that 
regulate HIF-1 activity are promising ways to modulate hypoxia signaling in cancer cells (15, 
16). 
Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) is a multifunctional 
protein that is involved in responses to oxidative stress, acting on both oxidative and alkylative 
DNA damage (via its endonuclease activity in base excision repair) (17-19) and augmenting 
activity of various transcription factors (via its redox signaling) (20-23), as well as contributing 
to clearance of RNA with damaged bases (24). APE1/Ref-1 expression and redox activity are 
increased in PDAC tissue, and its upregulation increases tumor cell migration, proliferation, and 
survival (17, 23). We previously demonstrated that APE1/Ref-1 redox activity regulates several 
transcription factors involved in pancreatic cancer signaling, including HIF-1α, as well as 
STAT3, and NFκB (20, 21).  
Carbonic Anhydrase IX (CA9) is a transmembrane protein that regulates pH in tumor 
cells under low oxygen conditions and contributes to cell proliferation and transformation (25, 
26). CA9 was reported to be an endogenous sensor to HIF-1 activity (27) and CA9 inhibitors 
were more potent in 3D culture due to the regions of hypoxia (28). One report demonstrated a 
strong correlation in vivo between pSTAT3 and CA9 expression and postulated that the 
regulation of CA9 by STAT3 could be important in invasion through IL-6 signaling (29). Both of 
these transcription factors are regulated by APE1/Ref-1, so the impact of APE1/Ref-1 redox 
activity on HIF1 activity as well as CA9 expression was evaluated in PDAC following exposure 
to hypoxia. 
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Here we describe the mechanisms by which APE1/Ref-1 regulates hypoxia signaling 
through HIF1α-mediated transcription. Inhibiting APE1/Ref-1 redox signaling with the selective 
inhibitor APX3330 (also called E3330) resulted in decreased STAT3 activity (20) and HIF1α 
activity (21) leading to decreased expression of CA9, a major HIF-1 target within cells (27). We 
also demonstrate that hypoxia stimulates interactions between APE1/Ref-1 and its redox targets, 
HIF1α and STAT3, but not NFκB in both PDAC tumor and stromal cells supporting our 
approach. 
We also show for the first time evidence using patient-derived tumor cells in the presence 
of appropriate stromal components, CAFs, 3D spheroid size and proliferation are dramatically 
reduced upon combination treatment with APE1/Ref-1 inhibitor, APX3330 and CA9 inhibitor, 
SLC-0111 (Clinical Trial NCT02215850) (30, 31). Upon blockade of multiple hypoxia signaling 
pathways with APX3330 and SLC-0111, we observe a dramatic effect on 3D tumor spheroid 
growth even in the presence of the protective environment of the CAFs. APE1/Ref-1 redox 
inhibitor APX3330 (20, 22, 32, 33) is slated for Phase 1 clinical trials in mid-2016, and the CA9 
inhibitor is currently in clinical trials. By decreasing APE1/Ref-1 redox activity we can impair 
the tumor cells’ response to hypoxia (21) and potentially improve the response to therapy. 
Therefore the combination of these agents may have proximate clinical applications. 
 
Methods and Materials: 
Cell Culture: Cells were maintained in culture as previously described (20-22). Patient-derived 
tumor cells, Pa03C, Pa02C, and Panc10.05 and CAF19 cells were a kind gift from Dr. Anirban 
Maitra (The Johns Hopkins University) (34). Upon receipt of the cells in 2011 as well as in June 
of 2015, we used STR analysis (CellCheck with IDEXX BioResearch) to confirm that we indeed 
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received the aforementioned cells from Dr. Maitra and that they were mycoplasma-free. MIA-
PaCa2 cells were purchased from and authenticated by ATCC (Manassas, VA). Cancer-
associated fibroblasts, UH1303-02 were isolated using the outgrowth method from patient tumor 
tissue as previously described (35). All patient-derived lines were passaged only 10 times before 
new stocks frozen prior to authentication were resuscitated. Hypoxia exposure was achieved 
using a Ruskinn Invivo2 200 hypoxia work station. CMV-EGFP-WT APE1/Ref-1 lentiviral 
construct was used to overexpress APE1/Ref-1 as previously described (36). To detect the cells 
for imaging, a CMV-EGFP lentiviral construct was used as previously described (36). 
Additionally, 150 pfu/cell of the pCL7TdTOMwo lentiviral vector was incubated with Pa03C 
and Panc10.05 cells for 48 hours to make cells stably express TdTomato.  
 
Western Blot Analysis: Western blots were performed as previously described (20-23) with 
antibodies for APE1/Ref-1 (Novus Biologicals; Littleton, CO), HIF1α (GeneTex; Irvine, CA), 
STAT1, STAT3, (Cell Signaling; Danvers, MA), NFκB (abcam; Cambridge, MA), CA9 (Santa 
Cruz; Dallas, Texas), Vinculin (Sigma; St. Louis, MO), and Actin (NeoMarkers; Fremont, CA). 
 
Co-immunoprecipitation: Samples were co-immunoprecipitated using the Pierce Co-IP kit 
(Thermo Scientific) with modifications as previously described (22). 
 
Transfection: PDAC and CAF cells were transfected with APE1/Ref -1 siRNA as previously 
described (20, 22, 23). siRNAs used were: #1 or scrambled control (previously reported) and two 
LifeTech validated siRNAs (#2: s1445 and #4: s1447) (22). APE1/Ref-1 siRNA #1 was used as 
the standard siRNA unless otherwise specified. 
on October 24, 2017. © 2016 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 17, 2016; DOI: 10.1158/1535-7163.MCT-16-0253 
  8
 
Transient Luciferase Reporter Assays: MIA-PaCa-2 cells were co-transfected with constructs 
containing luciferase driven by HIF1α and a Renilla luciferase reporter vector as previously 
described (22) using X-tremeGENE 9 DNA transfection reagent (Roche, Indianapolis, IN) along 
with siRNA as described above. Firefly and Renilla luciferase activities were assayed by using 
the Dual Luciferase Reporter Assay System (Promega Corp.) as before (20, 22). 
 
qRT-PCR Reactions: qRT-PCR was used to measure the mRNA expression levels of CA9 as 
previously described (21). Cells were treated with APE1/Ref-1 siRNA or increasing amounts of 
APX3330 in the presence or absence of hypoxia (1% and 0.2 % O2) for 24 h, then total RNA was 
extracted from cells using the QiagenRNeasy Mini kit (Valencia, CA) (37). First-strand cDNA 
synthesis and quantitative PCR were performed as previously described (21). The relative 
quantitative mRNA level was determined using the comparative Ct method using 18S rRNA, 
RPLP0, and B2M as reference genes (37, 38). The primers for CA9, 18S, RPLP0, and B2M are 
commercially available (Applied Biosystems).  
 
Inhibitors: Compounds were prepared and used as previously described: APX3330 (32, 33) and 
SLC-0111 (30, 31). The concentrations of APX3330 used are within clinically tolerated levels 
established previously by Eisai pharmaceutical company through a prior development program 
that evaluated the toxicology and phase I/II safety and clinical profile in non-cancer patients. 
Additionally, the SLC-0111 analog FC13-555A was synthesized as described in Supplemental 
Methods. The structure of each inhibitor can be seen in Supplemental Figure 1. 
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Cell Proliferation: PDAC cell proliferation in monolayer was measured using the Alamar Blue 
assay as previously described (22). Cells treated with APX3330 and SLC-0111 were exposed to 
hypoxia for six days followed by addition of Alamar Blue reagent (Invitrogen) and subsequent 
fluorescence analysis. Fold change refers to the fluorescence reading for cells treated with 
indicated inhibitors compared to cells growing in normal media. 
 
pH Assay: Intracellular pH was evaluated using the pHrodo Red AM Intracellular pH Indicator 
(LifeTech). PDAC cells treated with APX3330 and SLC-0111 were exposed to hypoxia for 48 
hours followed by analysis with pHrodo Red AM dye. Intracellular pH Calibration Buffers 
(LifeTech) were used to create a standard curve of fluorescence intensity for determination of pH 
values. Results were normalized to MTS analysis to account for changes in proliferation as 
before (20-22). Fluorescent images were acquired using a confocal/two-photon Olympus 
Fluoview FV-1000 MPE system (Olympus American) at the Indiana Center for Biological 
Microscopy facility (Indianapolis, IN). 
 
Statistical Analysis. qPCR data points for scrambled, siAPE1/Ref-1, and hypoxia treatments 
were analyzed using the 2ି∆∆஼೅  method and analysis of covariance (ANCOVA) models as 
previously described (22, 39). Data points in tests with multiple treatment groups were analyzed 
using post-hoc Multiple Comparisons Tests (Tukey, Dunnett, or Sidak as appropriate). For 
evaluation of data curves using multiple drugs, an extra-sum-of-squares F test was used to 
compare the goodness-of-fit of a nonlinear regression curve shared between groups with that of 
separate curves for each group. Differences between the treatment groups and control group were 
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considered significant if p<0.05 following Bonferroni corrections as appropriate. Statistical 
analyses were performed using SAS (Version 9.3, Copyright ©2010 SAS Institute Inc. Cary, 
NC) and Prism (Version 6.0f, Copyright ©2014 GraphPad Software Inc. La Jolla, CA). 
 
HIF-1 -/- MEF Generation: HIF-1-floxed mouse embryonic fibroblast (MEF) cells were 
generated as previously reported (40) and transduced with Ad-CMV-Cre (Cre adenovirus) or Ad-
GFP (control) vector (Vector BioLabs; Malvern, PA) for 24 hours using 5 ng/mL polybrene to 
produce HIF-1-deficient cells (40). PCR was used to verify the deletion of HIF (Supplemental 
Figure 2). 
 
3D Co-Cultures: Ultra low attachment 96-well plates (Corning Inc., Life Sciences) were used to 
generate 3-dimensional tumor spheroids in the presence and absence of CAFs (75 μL/well) as 
described previously (41, 42). Cells were stably transduced with EGFP (green) or TdTomato 
(red) as indicated to preserve the genetic characteristics of the low passage patient cells (34, 42). 
Cells were re-suspended in colorless DMEM growth media containing 3% Reduced Growth 
Factor Matrigel (RGF, BD Biosciences) and 5% FBS. Following plating, cells were treated on 
Days 4 and 8 with media containing 5% serum, 3% RGF Matrigel, and inhibitors as indicated. 
On Day 12, spheroids were analyzed using Thermo ArrayScan high-content imaging system 
(43). Images of 3D structures were captured by ArrayScan using a 2.5x objective for TdTomato 
and EGFP; then 2D projections were processed to quantify differences in total intensity and total 
area of both CAFs and tumor.  
 
Results 
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APE1/Ref-1 interactions with HIF1α and STAT3 are stimulated by hypoxia 
We previously published data demonstrating decreased STAT3, HIF1α, and NFκB activity 
following knockdown of APE1/Ref-1 and/or inhibition of APE1/Ref-1 redox signaling with the 
selective inhibitor APX3330 (also called E3330) (20, 21).  Similarly, we found that inhibition of 
APE1/Ref-1 led to a decrease in a major HIF-1 target within cells, Carbonic Anhydrase IX 
(CA9) (21, 28). To further dissect the role of APE1/Ref-1 in hypoxia signaling and more clearly 
determine whether hypoxia stimulates interactions between APE1/Ref-1 and its redox targets, 
endogenous APE1/Ref-1 was immunoprecipitated from lysates of two low passage PDAC cell 
lines (Panc10.05 and Pa03C) under normoxic and hypoxic (0.2% O2) conditions. These cell lines 
are representative of ductal adenocarcinoma, were previously sequenced (34), and have the 
common G12D mutation in KRAS as well as missense mutations in p53. Panc10.05 was derived 
from a primary PDAC tumor, is wt for p16(INK4A), but has a SMAD4 deletion; however Pa03C 
was isolated from a metastatic lesion in the liver and is wt for both p16(INK4A) and SMAD4. 
IPs were probed for HIF1α, STAT3, and NFκB. HIF1α and STAT3, but not NFκB were 
detected in the pull-down fractions under hypoxic conditions, but these interactions were not 
detected under normoxic conditions (Figure 1A-B). Controls of TNFα (NFκB) and IL-6 
(STAT3) were performed to show that interactions between APE1/Ref-1 and the transcription 
factors it regulates do indeed occur under normoxic conditions with appropriate stimulation 
(Supplemental Figure 3). Interactions of APE1/Ref-1 with HIF1α and STAT3 were obvious 
under hypoxic conditions. 
With overexpression of APE1/Ref-1, the interaction with HIF1α and STAT3 remained intact  
while NFκB was still not detected in IPs from cells overexpressing APE1/Ref-1 following 
exposure to hypoxia indicating that the amount of APE1/Ref-1 was not limiting in the above 
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panels (Figure 1C-D). To demonstrate that APE1/Ref-1’s interactions with the transcription 
factors are specific to signaling in hypoxia, we probed for another STAT family member, 
STAT1. IPs from 10.05 cells were probed for STAT1, which was not detected regardless of the 
levels of APE1/Ref-1 or oxygen conditions (Figure 1C). Due to the complexity of the disease 
and the signaling between various cell types in the pancreatic tumor microenvironment, we 
investigated APE1/Ref-1 interactions with HIF1α, STAT3, and NFκB in CAFs. These CAFs are 
non-tumorigenic and although they have activated signaling pathways due to their association 
with the tumor, they are non-transformed. The results were identical to the result with PDAC 
cells: APE1/Ref-1 interacts with HIF1α and STAT3 under hypoxia, but not NFκB 
(Supplemental Figure 4). In light of CA9 inhibitors beginning clinical trials and our previous 
data demonstrating transcriptional regulation of CA9 following APE1/Ref-1 blockade (21), we 
focused these studies on HIF1α signaling and the regulation of the downstream molecule CA9 
through APE1/Ref-1. 
 
APE1/Ref-1 protein expression contributes to hypoxia-induced HIF1α-mediated 
transcription 
 To show that the interactions between APE1/Ref-1 and HIF1α are functionally 
important, we evaluated the contribution of APE1/Ref-1 to HIF-1 transcriptional activity by co-
transfecting MIA PaCa-2 cells with HIF1α-driven firefly luciferase or pLuc-MCS (vector 
control) alongside APE1/Ref-1 siRNA or scrambled control and exposing cells to hypoxia for 24 
hrs. APE1/Ref-1 knock-down resulted in a significant reduction (~47%) in hypoxia-induced 
HIF1α activity (Figure 2A-B). 
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Effects of APE1/Ref-1 on HIF transcriptional activity were further evaluated by 
examining hypoxia-mediated transcription of HIF-1 target, CA9. We compared CA9 mRNA 
levels in two PDAC cell lines and one pancreatic CAF cell line following APE1/Ref-1 knock-
down and exposure to hypoxia. Bar graph represents the fold change of mRNA expression level 
of CA9. Hypoxia-induced CA9 mRNA levels were attenuated by APE1/Ref-1 knock-down in all 
cell lines at both levels of hypoxia (Figure 2C-E). Variability in the amount of induction in 
different cell lines may be partially attributable to the extremely low baseline CA9 expression 
under normoxic conditions. APE1/Ref-1 knock-down similarly attenuated CA9 mRNA levels 
under hypoxic conditions in two additional primary PDAC cell lines (Supplemental Figure 5). 
These results were validated in MIA-PaCa-2 cells exposed to hypoxia using two additional 
APE1/Ref-1-targeting siRNAs, and similar results were obtained (Figure 2F-G). To verify the 
reduction in CA9 also occurred at the protein level, hypoxia-induced CA9 protein levels were 
evaluated via western blot following APE1/Ref-1 knock-down in PDAC cells and pancreatic 
CAF cells. APE1/Ref-1 knock-down resulted in a ~70% reduction in hypoxia-induced CA9 
protein levels (Figure 2H-I). 
 
Hypoxia-induced CA9 transcription is HIF-1-dependent 
To confirm that the effects of APE1/Ref-1 and hypoxia on CA9 transcription were mediated 
by HIF-1 activity, we evaluated hypoxia-induced CA9 mRNA levels in HIF-1-deficient (-/-) 
MEFs following APE1/Ref-1 knock-down. As expected, in HIF-1 proficient MEFs, CA9 is 
induced 30-fold compared to normal oxygen controls. In HIF-1 -/- MEFs CA9 mRNA levels 
were not induced by exposure to hypoxia (Figure 3A), or affected by APE1/Ref-1 knock-down 
(Figure 3B), indicating that CA9 transcription is HIF-1-dependent, regardless of APE1/Ref-1 
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expression or oxygen levels. HIF-1 depletion in these cells was confirmed by PCR 
(Supplemental Figure 2). 
 
Inhibition of APE1/Ref-1 redox signaling affects CA9 transcription 
As a multi-functional protein, APE1/Ref-1 is also involved in base excision repair (BER) 
of DNA lesions, RNA quality control, and reduction-oxidation (redox) regulation. Knock-down 
of APE1/Ref-1 affects all of these functions. We therefore examined whether the redox function 
is responsible for the APE1/Ref-1-mediated regulation of hypoxia signaling pathways using an 
APE1/Ref-1 specific redox inhibitor that does not affect other APE1/Ref-1 functions (44, 45) and 
is slated for clinical trial in the summer of 2016. We previously showed that APX3330 decreases 
CA9 mRNA levels in Panc-1 and MIA-PaCa2 cells exposed to hypoxia (21). Here we expand 
these results to primary cells and CAF cells, as well as 3D co-cultures. Following treatment with 
APX3330 and exposure to hypoxia, CA9 mRNA levels in Pa03C cells and in pancreatic CAF 
cells were attenuated in a dose-dependent manner (Figure 3C-D). Additionally, CA9 protein 
expression was measured in a 3D co-culture model following inhibition of APE1/Ref-1 with 
APX3330. While CA9 was not detected under normoxic conditions in the patient-derived Pa03C 
cells in monolayer, when grown as spheroids, these cells now express CA9. Tumor spheroids 
grown in the presence of CAFs more strongly upregulated CA9 expression ~3-fold, likely due to 
larger spheroids containing larger regions of hypoxia, as well as the more complex signaling 
present with the stromal elements. Inhibition of APE1/Ref-1 redox signaling with APX3330 led 
to decreased CA9 expression in 3D tumor cultures in a dose-dependent manner, both in the 
presence and absence of CAF cells (Figure 3E). These data support the use of the 3D co-culture 
system for preclinical studies validating novel targets like CA9 and APE1/Ref-1 in PDAC. 
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Importantly, we evaluated CA9 and APE1/Ref-1 protein expression following exposure 
to hypoxia (0.2% oxygen) in three PDAC cell lines and found that, while CA9 levels increased 
over time, APE1/Ref-1 levels did not change significantly (Supplemental Figure 6), indicating 
that hypoxia-induced CA9 expression is not secondary to APE1/Ref-1 upregulation. 
 
Dual-targeting of CA9 and APE1/Ref-1 acidifies PDAC cells and inhibits cell viability 
under hypoxia 
 CA9 regulates intracellular pH under hypoxic conditions, and APE1/Ref-1 redox activity 
contributes to hypoxia-induced CA9 expression. We analyzed intracellular pH in hypoxia-
exposed PDAC cells following treatment with CA9 inhibitor, SLC-0111 and the APE1/Ref-1 
redox inhibitor, APX3330 using the pHrodo Red AM fluorescent pH indicator as a functional 
endpoint for carbonic anhydrase activity under hypoxic conditions. The analysis of intracellular 
pH was performed at an early timepoint (48 hr exposure to inhibitors and hypoxia) to avoid 
drastic changes in cell survival. Still, some viability changes were observed (Supplemental 
Figure 7), so these changes were taken into account in the analysis and normalization of the 
intracellular pH data. Dual-treatment with SLC-0111 and APX3330 results in a greater decrease 
in intracellular pH than treatment with either inhibitor alone (Figure 4A-B). 
 Inhibition of APE1/Ref-1 redox activity results in a dose-dependent decrease in PDAC 
cell viability following treatment of cells with APX3330 and hypoxia. Remarkably, the effect of 
APE1/Ref-1 inhibition on cell viability is greatly enhanced by treating with the CA9 inhibitor, 
SLC-0111 in addition to APX3330 treatment under hypoxia (Figure 4C). In support of these 
results, new CA9 inhibitors are being developed and the combination of APX3330 with SLC-
0111 analog, FC13-555A is also significantly effective at killing PDAC cells in monolayer 
on October 24, 2017. © 2016 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 17, 2016; DOI: 10.1158/1535-7163.MCT-16-0253 
  16
(Figure 4D), supporting the hypothesis that blockade of hypoxia signaling proteins will be 
deleterious to PDAC cells.  
 
Dual-targeting of CA9 and APE1/Ref-1 inhibits PDAC tumor growth in a 3D co-culture 
model 
 In order to more accurately mimic the tumor microenvironment, we utilized a three-
dimensional co-culture model of PDAC that included the low passage patient derived tumor cells 
as well as cancer-associated fibroblasts. As demonstrated above, the levels of CA9 were greater 
in these tumor spheroids when grown with CAF cells, and CA9 expression was attenuated by 
treatment with APX3330 (Figure 3E). Inhibition of CA9 with SLC-0111 was more potent in the 
3D model with dramatic effects on tumor cell killing observed at lower doses than in monolayer, 
as measured by reductions in area of patient-derived cells (Figure 5A-B). Cell killing was more 
dramatic in the tumor cells than in the CAFs, especially when CAF19 cells were in co-culture 
with Pa03C cells. Although these CAFs have aberrantly activated signaling pathways, they are 
non-tumorigenic and suggest that tumor cells are more greatly affected by the dual targeting 
approach as compared to normal cells. Similar trends were seen when measuring fluorescence 
intensity (data not shown). Importantly, inhibition of CA9 can effectively kill tumor cells even 
when in the protective environment of the CAFs.  
To determine if blockade of STAT3 and HIF-mediated transcription alongside the 
inhibition of CA9 activity would potentiate PDAC cell death, we combined APX3330 and SLC-
0111 in the 3D co-culture model. We can assess the effects of dual targeting on both the tumor 
alone and the tumor and CAFs in co-culture due to the different fluorescent labels in each cell 
type. As seen in hypoxia-exposed 2D cultures, addition of CA9 inhibition to APE1/Ref-1 redox 
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inhibition resulted in dramatic potentiation of the cell killing in the tumor spheroids. Spheroids 
composed of patient-derived PDAC cells (Pa03C or Panc10.05 – labeled red) and CAF cells 
(labeled green) were treated with APX3330 and SLC-0111 (Figure 5E-F), and the graphical 
representation i.e. area of red and green fluorescence were evaluated separately as markers for 
each cell type and is shown in Figure 5C-D. Dramatic enhancement of the APX3330-induced 
blockade of spheroid growth was observed with the addition of CA9 inhibition. The observed 
decrease in tumor cell area with APX3330 treatment was significantly different in the presence 
of SLC-0111, validating the effects seen in hypoxia-exposed 2D cultures. Similar trends were 
seen when measuring red and green fluorescence intensity (data not shown). 
 
Discussion: 
Elevated APE1/Ref-1 expression is associated with numerous cancers, including 
pancreatic, ovarian, gastric, breast, lung, glioblastoma, liver, and colon (18, 19, 46), and analysis 
of publicly available data from The Cancer Genome Atlas (TCGA, cancergenome.nih.gov) 
reveals a significant decrease in survival of PDAC patients with elevated APE1/Ref-1 expression 
(Supplemental Figure 8A, more information in Supplemental Methods) (47, 48). In tumor cells, 
reduction-oxidation (redox) of thiols of cysteines in various tumor-promoting transcription 
factors such as STAT3, NFκB, and HIF-1 by APE1/Ref-1 is a crucial step in the activation of 
these factors. These TFs are all important targets in cancer therapy and particularly PDAC, but 
have been shown to be particularly hard to drug (18, 20, 21, 46, 49, 50). While previous studies 
by us and others (23, 51, 52) have demonstrated the effect of APE1/Ref-1 knockdown on tumor 
cell growth and survival, additional studies have demonstrated the effectiveness of a small 
molecule, APX3330, in targeting and blocking the redox signaling activity of APE1/Ref-1. 
on October 24, 2017. © 2016 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on August 17, 2016; DOI: 10.1158/1535-7163.MCT-16-0253 
  18
APX3330 has been shown in multiple in vitro and in vivo models of pancreatic cancer to be 
effective in reducing tumor volume and metastases as both a single agent and in combination 
with gemcitabine (20, 21, 53). The mechanism of action has been extensively investigated and 
the drug has a direct and selective interaction with APE1/Ref-1 as demonstrated by chemical 
footprinting, mass spectrometry, and other biochemical analyses (33, 44, 54). Importantly, while 
APX3330 blocks APE1/Ref-1’s redox function, it has no effect on APE1/Ref-1 endonuclease 
DNA repair activity (45). Although multiple pathways may be modulated, unacceptable toxicity 
following APE1/Ref-1 inhibition has not been observed in animal or human studies (21, 55). 
APX3330 is slated for a Phase 1a/1b clinical trial of a dose-escalation study of APX3330 in 
patients with advanced solid tumors and a dose-expansion cohort of patients with advanced 
PDAC in mid-2016 in PDAC patients. Therefore, targeting APE1/Ref-1 with APX3330 has a 
great deal of potential in cancer therapy. 
We previously demonstrated that APE1/Ref-1 contributes to STAT3 activation and the 
consequent tumor-promoting effects of STAT3 in PDAC cells (20). The cooperative activities of 
STAT3 and HIF-1 have been demonstrated in a variety of cancers (56, 57); however the finding 
that APE1/Ref-1 binding to STAT3 is stimulated by exposure to hypoxia in PDAC cells, 
presented here for the first time, further indicates the importance of both APE1/Ref-1 and 
STAT3 as potential therapeutic targets in PDAC. These findings will be further pursued with 
preclinical STAT3 inhibitors that are being developed for eventual clinical trials (42). 
Furthermore, our results demonstrating that APX3330 treatment decreases hypoxia-induced HIF-
1 transcriptional activity and CA9 mRNA levels (21) is exciting since CA9 inhibitors are either 
entering or are in clinical trials. This latter finding is of great interest, not only because it is 
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closer to patient applicability, but builds upon our strategy of blocking various signaling 
pathways at multiple points along pathways influenced by APE1/Ref-1. 
CA9 is one of only two tumor-associated carbonic anhydrase isoenzymes known, and it 
has similarly been established as a potential therapeutic cancer target (25, 26, 30). CA9 is not 
detected in most normal tissues, but its expression in renal and other cancers often indicates 
locally advanced, hypoxic tumors and poor treatment response (58, 59). Variations in CA9 
expression by region in tumor samples make whole-tissue analysis difficult (60, 61), but analysis 
of publicly available data from Oncomine (oncomine.org) using microdissected samples reveals 
upregulation of CA9 in PDAC tissue samples, as compared to normal pancreas and pancreatic 
cancer precursor samples (Supplemental Figure 8B-D) (62, 63). Furthermore, the CA9 inhibitor 
SLC-0111 is in clinical trials to evaluate its safety and efficacy in patients with advanced solid 
tumors, including pancreatic cancer (clinicaltrials.gov ID: NCT02215850). Therefore, our 
strategy of inhibiting the HIF-CA9 axis at two points; blocking HIF-1 production of CA9 with 
APX3330 as well as blocking the activity of any CA9 that is produced using SLC-0111 (Figure 
6), is a novel approach to the targeting of hypoxic PDAC cells. That being said, not only hypoxic 
PDAC cells will be sensitive to the combination of APX3330 and SLC-0111. APX3330 is 
targeting other signaling pathways that are activated in tumor cells that are fully oxygenated, and 
SLC-0111 can also inhibit CA12, another tumor-associated carbonic anhydrase (31). Our 
findings establish this strategy resulting in additive cell acidification and inhibition of hypoxic 
PDAC cell proliferation. This combination approach is similar to the results we previously 
published using APX3330 and STAT3 inhibition as a dual hit strategy in PDAC cells (20) and 
APX3330 (HIF-1 inhibition) and Avastin (bevacizumab) for VEGF-signaling inhibition as an 
anti-angiogenesis combination strategy (45, 64, 65). 
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As discussed, APX3330 will soon be entering clinical trials for general solid tumors as 
well as pancreatic cancer. Since SLC-0111 is already in clinical trials with other CA9 inhibitors 
queued up to enter the clinic, our data demonstrating a novel two pronged approach targeting 
highly hypoxic pancreatic cancer could be clinically applicable in the foreseeable future. 
Additionally, given data demonstrating elevated expression of APE1/Ref-1, STAT3, and CA9 in 
a variety of other solid tumors (59, 66), these combination approaches should have applicability 
beyond pancreatic cancer (30, 32, 59).  
In conclusion, the data presented here provides continued evidence of the close 
relationship between APE1/Ref-1, STAT3, and HIF-1 signaling and CA9 production in PDAC as 
well as the first evidence that the combination of two small molecule inhibitors, each showing 
minimal toxicity, may be an important next step in the treatment of PDAC, a disease for which 
effective treatment remains elusive. 
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Figure Legends: 
Figure 1: APE1/Ref-1 interactions with HIF1α and STAT3 are stimulated by hypoxia in 
PDAC cells 
Cell extracts were prepared from Panc10.05 (A) and Pa03C (B) cells and also from cells that 
overexpress APE1/Ref-1 (C, D) following exposure to hypoxia (0.2%) for 24 hr. Extracts were 
immunoprecipitated with anti-APE1/Ref-1 antibody or IgG.  The immunoprecipitated complexes 
were then probed for HIF1α, STAT3, NFkB, STAT1, or APE1/Ref-1. n = 3-4 per experiment. 
Typical results shown. 
 
Figure 2: APE1/Ref-1 protein expression contributes to hypoxia-induced HIF1α-mediated 
transcription 
MIA-PaCa2 cells were assayed for HIF1 activity using a luciferase and Renilla reporter assay 
following  APE1/Ref-1 knock-down. A. Knock-down of APE1/Ref-1 was confirmed via western 
blot. B. HIF1α-driven luciferase expression was evaluated following hypoxia (24 hr, 0.2% 
oxygen vs. normoxia controls; n=3). C-E. Following APE1/Ref-1 knock-down and 24 hrs in 
hypoxia, CA9 mRNA levels were evaluated via qPCR in the cell lines described (n=3). F. 
APE1/Ref-1 knock-down in MIA-PaCa2 cells with three different siRNAs was confirmed via 
western blot. G. CA9 mRNA levels were evaluated via qPCR in SC and knocked-down samples 
from three siRNAs following hypoxic conditions (24 hrs, 0.2% oxygen vs. normoxia controls; 
representative experiment of n=3). H-I. CA9 protein levels were evaluated via western blot in 
10.05 and CAF19 cells following transfection with SC or APE1/Ref-1 siRNA and hypoxia (24 
hr, 1% oxygen, representative blots of n=3). *p<0.001 (Tukey’s Multiple Comparisons Test); 
**p<0.01 & #p<0.001 (ANCOVA). For CA9 western blots (H-I), p<0.05 for SC vs. siAPE under 
hypoxia (Tukey’s Multiple Comparisons Test). 
 
Figure 3: APE1/Ref-1 redox signaling affects CA9 transcription in a HIF-1-dependent 
manner 
A. HIF-1-proficient (+/+) and HIF-1-deficient (-/-) mouse embryonic fibroblasts (MEFs) were 
exposed to 0.2% oxygen for 24 hrs, and CA9 mRNA levels were evaluated by qPCR, 
representative experiment of n=3. B. HIF-1 -/- MEFs were transfected with SC or APE1/Ref-1-
directed siRNA and incubated at 0.2% oxygen for 24 hrs and CA9 mRNA levels were evaluated 
via qPCR, representative experiment of n=3. C-D. CA9 mRNA levels were evaluated via qPCR 
following APX3330 treatment and hypoxia (24 hr, 1% oxygen; representative graph of n=3). E. 
Pa03C cells were collected from monolayer (2D) cultures and 3D tumor spheroid cultures grown 
in the presence or absence of CAFs following treatment with APX3330, and CA9 protein levels 
were evaluated via western blot (representative blot of n=2). *p<0.01 & **p<0.001 (Tukey’s 
Multiple Comparisons Test). 
 
 
Figure 4: Dual-targeting of CA9 and APE1/Ref-1 acidifies PDAC cells and inhibits cell 
viability under hypoxia 
A. Panc10.05 cells were treated with APX3330 and SLC-0111 and exposed to hypoxia (0.2% 
O2) for 48 hrs prior to analysis of intracellular pH (Avg + SE, n=3). Representative images from 
pH experiments are shown in B. C-D. Viability assay of Pa02C cells treated with the indicated 
concentrations of APX3330 and CA9 inhibitors, SLC-0111 or FC13-555A and exposed to 
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hypoxia (0.2%) for six days (Avg + SE, n=6). Fold change refers to the comparison of each data 
point to the fluorescence of untreated tumor cells. *p<0.05 & **p<0.01 (Dunnett’s Multiple 
Comparisons Test); #p<0.05 & ##p<0.01 (Sidak’s Multiple Comparisons Test). Additionally, 
differences in nonlinear regression curves between treatment groups were confirmed using extra-
sum-of-squares F tests followed by Bonferroni Corrections in each experiment (p<0.05 for all 
dual-treatment curves vs. single-agent curves). 
 
Figure 5: Dual-targeting of CA9 and APE1/Ref-1 inhibits PDAC tumor growth in a 3D co-
culture model 
Pa03C (A, C, & E) and Panc10.05 (B, D, & F) tumor cells were grown in 3D cultures in the 
presence and absence of CAFs. Spheroids were treated with SLC-0111 alone (A & B) and in 
combination with APX3330 (C & D), and the area of tumor (red) and CAF (green) were 
quantified following 12 days in culture, n=3-4. Representative images from dual-treatment 
experiments are shown in E and F. Differences in nonlinear regression curves between treatment 
groups were confirmed using extra-sum-of-squares F tests followed by Bonferroni Corrections in 
dual-treatment experiments (p<0.01 for each curve vs. the curve for APX3330 alone in tumor 
cells alone; p<0.01 for curves with 50 μM SLC-0111 vs. the curve for APX3330 alone in tumor 
+ CAF co-cultures). 
 
Figure 6: Schematic demonstrating the effects of APE1/Ref-1 - CA9 dual targeting on 
cellular acidification and downstream signaling. 
Inhibition of APE1/Ref-1 redox signaling with APX3330 results in decreased DNA binding of 
transcription factors including HIF-1 (as well as STAT3 and NFκB). HIF-1 transactivation is 
stimulated under low oxygen conditions, resulting in transcription of tumor-promoting factors, 
including CA9. CA9 catalyzes the conversion of carbon dioxide and water to bicarbonate and 
hydrogen ions, resulting in stabilization of intracellular pH, which promotes cell survival under 
hypoxic conditions. Inhibition of CA9 activity with SLC-0111 promotes cell killing via 
acidification, and this inhibition is enhanced by APX3330 due to a decrease in CA9 expression 
as well as inhibition of other key signaling pathways via STAT3, NFκB, and AP-1. 
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